An open-label Phase I dose-escalation study to characterize the safety, tolerability, pharmacokinetics, and maximum tolerated dose of BAY 1143572 given in a once-daily or an intermittent dosing schedule in subjects with advanced malignancies
A study for patients with solid tumor and malignant lymphomas using study drug BAY 1143572
Sponsor: Bayer
Enrolling: Male and Female Patients
IRB Number: AAAO2313
U.S. Govt. ID: NCT01938638
Contact: Palak Thaker: 212-305-2055 / pt2433@cumc.columbia.edu
Additional Study Information: The primary purpose of this research study is to evaluate the safety, tolerability and maximum tolerated dose of BAY 1143572. Moreover, concentrations of BAY 1143572 as well as of biomarker proteins may provide information about the effects of BAY 1143572, will be determined in blood and tumor tissue.
This study is closed
Investigator
Gary Schwartz, MD
Do You Qualify?
Have you been diagnosed with an advanced cancer such as solid tumors and malignant lymphomas? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Palak Thaker
pt2433@cumc.columbia.edu
212-305-2055
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE